Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -24.55%71.08M | -4.66%94.95M | -64.98%73.57M | 8.79%760.75M | 271.39%371.82M | -44.70%94.21M | -70.15%99.58M | 120.79%210.11M | 156.58%699.3M | -16.46%100.12M |
| Cost of revenue | -16.67%56.99M | -3.84%68.69M | -70.09%50.67M | 3.28%616.99M | 225.70%307.59M | -48.59%68.39M | -75.51%71.43M | 119.74%169.42M | 170.55%597.39M | 4.03%94.44M |
| Gross profit | -45.43%14.09M | -6.73%26.26M | -43.72%22.9M | 41.05%143.75M | 1,032.02%64.23M | -30.87%25.82M | -32.90%28.15M | 125.26%40.69M | 96.98%101.91M | -80.47%5.67M |
| Operating expense | 2.29%10.48M | 29.61%12.15M | -23.30%11.79M | 11.71%52.05M | -69.33%13.85M | -30.13%10.24M | -34.45%9.37M | 96.66%15.37M | 32.20%46.59M | 179.77%45.15M |
| Selling and administrative expenses | 2.17%9.45M | 75.49%12.67M | -24.58%10.83M | 15.94%50.67M | -70.82%12.86M | -32.75%9.25M | -29.06%7.22M | 107.98%14.36M | 24.00%43.7M | 134.23%44.07M |
| -Selling and marketing expense | 1.58%2.71M | 120.12%4.32M | -25.79%1.65M | 71.34%9.93M | 95.69%3.09M | 33.55%2.66M | 31.66%1.96M | 201.77%2.22M | -4.04%5.8M | -63.14%1.58M |
| -General and administrative expense | 2.41%6.75M | 58.83%8.35M | -24.36%9.18M | 7.46%40.74M | -77.00%9.77M | -43.99%6.59M | -39.48%5.26M | 96.81%12.14M | 29.80%37.91M | 192.32%42.49M |
| Depreciation and amortization | 3.43%1.03M | -9.75%935K | -5.15%958K | 4.82%4.02M | -8.53%986K | 9.87%991K | 9.40%1.04M | 10.87%1.01M | --3.84M | --1.08M |
| -Depreciation | 3.43%1.03M | -9.75%935K | -5.15%958K | 4.82%4.02M | -8.53%986K | 9.87%991K | 9.40%1.04M | 10.87%1.01M | --3.84M | --1.08M |
| Other operating expenses | ---- | ---- | ---- | -52.12%1.38M | ---- | ---- | -64.86%1.11M | ---- | --2.89M | ---- |
| Total other operating income | ---- | --1.46M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Operating profit | -76.82%3.61M | -24.86%14.11M | -56.11%11.12M | 65.77%91.7M | 227.64%50.39M | -31.35%15.58M | -32.11%18.78M | 147.06%25.33M | 235.41%55.32M | -405.54%-39.48M |
| Net non-operating interest income (expenses) | 50.46%1.79M | 2.94%1.4M | -5.52%1.27M | 0.41%4.93M | -3,300.00%-2.24M | 1,072.95%1.19M | 965.61%1.36M | 1,573.63%1.34M | 3,564.66%4.91M | -109.64%-66K |
| Non-operating interest income | 338.78%6.31M | 293.25%6.36M | 347.84%6.64M | 5.90%5.66M | ---- | --1.44M | --1.62M | --1.48M | 531.63%5.34M | ---- |
| Non-operating interest expense | 1,696.83%4.53M | 1,828.40%4.96M | 3,708.51%5.37M | 2,387.45%390.7K | 3,300.00%2.24M | 106.56%252K | 63.69%257K | 54.95%141K | -95.67%15.71K | 135.00%66K |
| Total other finance cost | ---- | ---- | ---- | -18.96%340.89K | ---- | ---- | ---- | ---- | 20.37%420.64K | ---- |
| Net investment income | ||||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | -29.89%46.71K | 66.61K | ||||||||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | 110.20%2.98M | -29,625.91%-29.27M | ||||||||
| Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---5.78M | ---- |
| Less:Write off | ---- | ---- | ---- | -108.51%-2.98M | ---- | ---- | ---- | ---- | 35,497.05%35.05M | ---- |
| Other non-operating income (expenses) | -97.20%101K | 93.91%605K | 125.47%355K | 114.21%1.33M | -39.16%1.75M | -34.99%3.61M | -83.39%312K | -178.01%-1.39M | 107.97%622.83K | 365.44%2.87M |
| Income before tax | -73.01%5.5M | -21.20%16.12M | -49.60%12.74M | 219.12%100.99M | 236.06%49.89M | -27.55%20.38M | -30.40%20.45M | 111.55%25.28M | 263.13%31.65M | -395.14%-36.67M |
| Income tax | 2.38%1.37M | 1.81%1.8M | -81.66%600K | -4.34%9.98M | 274.00%18.3M | -34.70%1.34M | -42.23%1.77M | 108.34%3.27M | 113.27%10.44M | 31.46%4.89M |
| Net income | -78.33%4.13M | -23.38%14.32M | -44.84%12.14M | 329.07%91.01M | 176.02%31.59M | -26.99%19.03M | -29.02%18.69M | 112.04%22.01M | 455.01%21.21M | -577.55%-41.56M |
| Net income continuous operations | -78.33%4.13M | -23.38%14.32M | -44.84%12.14M | 329.07%91.01M | 176.02%31.59M | -26.99%19.03M | -29.02%18.69M | 112.04%22.01M | 455.01%21.21M | -577.55%-41.56M |
| Noncontrolling interests | -42.68%-234K | 267.04%299K | -43.35%-248K | 81.89%-758.16K | 93.43%-242K | 5.20%-164K | -2.29%-179K | -9.49%-173K | -398.70%-4.19M | -463.25%-3.68M |
| Net income attributable to the company | -77.29%4.36M | -25.69%14.02M | -44.15%12.39M | 261.32%91.77M | 184.05%31.84M | -26.85%19.2M | -28.81%18.86M | 110.50%22.18M | 444.87%25.4M | -504.85%-37.88M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -77.29%4.36M | -25.69%14.02M | -44.15%12.39M | 261.32%91.77M | 184.05%31.84M | -26.85%19.2M | -28.81%18.86M | 110.50%22.18M | 444.87%25.4M | -504.85%-37.88M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -76.80%0.0029 | -25.41%0.0091 | -44.44%0.008 | 261.21%0.0596 | 184.15%0.0207 | -26.90%0.0125 | -29.07%0.0122 | 111.76%0.0144 | 450.00%0.0165 | -510.00%-0.0246 |
| Diluted earnings per share | -76.80%0.0029 | -25.41%0.0091 | -44.44%0.008 | 261.21%0.0596 | 184.15%0.0207 | -26.90%0.0125 | -29.07%0.0122 | 111.76%0.0144 | 450.00%0.0165 | -510.00%-0.0246 |
| Dividend per share | -33.33%0.004 | -33.33%0.004 | -25.00%0.006 | 271.43%0.026 | 0.00%0.006 | 0.006 | 500.00%0.006 | 0.008 | 0.007 | 0.006 |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.